Antiplaque Comments
This article was originally published in The Rose Sheet
Executive Summary
New date for comments on advance notice of proposed rulemaking for OTC Antigingivitis/ Antiplaque Drug Products is Nov. 25, FDA announces. Reply comment period also has been extended to Feb. 23, 2004, agency says in Federal Register notice slated to appear Aug. 25. CHPA, CTFA jointly requested the extension in a July 15 petition (1"The Rose Sheet" July 28, 2003, In Brief). Groups wanted extra time to review data on ingredients the agency has proposed classifying as Category III (insufficient data) rather than Category I (safe and effective)...
You may also be interested in...
CTFA oral health care petition
Comment extension for OTC antigingivitis/antiplaque drug products proposed monograph requested by the Cosmetic, Toiletry & Fragrance Association and the Consumer Healthcare Products Association in July 15 petition to FDA. Delaying due date for comments by 90 days to Nov. 25, instead of Aug. 25, would allow industry to prepare material addressing FDA's decision to classify several active ingredients as Category III, rather than Category I, the groups state. CTFA, CHPA also request 90-day delay of the reply comment period. Associations argue industry needs time to reply to agency's call for statistical protocol and efficacy data on certain combination products before tentative final monograph is published. Notice of proposed rulemaking was published May 29 (1"The Rose Sheet" June 2, 2003, p. 3)...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.